PULMATRIX, INC. Shareholders' Equity
PULMATRIX, INC. (PULM) had Shareholders' Equity of $2.56 million as of 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-09-17
- 2026-06-30: Stockholders' Equity Attributable to Parent $2.56M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $3.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $3.81M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $4.73M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $2.56M S-4/A · filed 2026-09-17 | |
| 2026-03-31 | $3.59M S-4/A · filed 2026-09-17 | |
| 2025-12-31 | $3.81M S-4/A · filed 2026-09-17 | |
| 2025-09-30 | $4.73M 10-Q · filed 2025-10-16 | |
| 2025-06-30 | $5.60M S-4/A · filed 2026-09-17 | |
| 2025-03-31 | $7.15M S-4/A · filed 2026-09-17 | |
| 2024-12-31 | $8.95M S-4/A · filed 2026-09-17 | |
| 2024-09-30 | $10.92M 10-Q · filed 2025-10-16 | |
| 2024-06-30 | $13.31M 10-Q · filed 2025-10-16 | |
| 2024-03-31 | $19.02M 10-Q · filed 2025-10-16 | |
| 2023-12-31 | $18.00M S-4/A · filed 2026-09-17 | |
| 2023-09-30 | $19.88M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $23.45M 10-Q · filed 2024-11-08 | |
| 2023-03-31 | $27.01M 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $31.11M 10-K · filed 2025-03-21 | |
| 2022-09-30 | $35.05M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $38.44M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $42.76M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $47.45M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $45.19M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $53.09M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $56.65M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $23.14M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $23.50M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $13.88M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $6.94M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $11.02M 10-K · filed 2022-03-29 | |
| 2019-09-30 | $14.73M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $18.09M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $10.20M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $11.84M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $12.63M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $16.80M 10-Q · filed 2019-11-01 | |
| 2018-03-31 | $7.53M 10-Q · filed 2019-11-01 | |
| 2017-12-31 | $10.14M 10-K · filed 2020-03-26 | |
| 2017-09-30 | $12.78M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $15.79M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $15.90M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $8.76M 10-K · filed 2019-02-19 | |
| 2016-09-30 | $17.47M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $20.15M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $28.17M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $32.61M 10-K · filed 2018-03-13 | |
| 2015-09-30 | $35.91M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $39.31M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $10.04M 10-K · filed 2015-06-10 | |
| 2014-12-31 | -$78.79M 10-K · filed 2017-03-10 | $11.30M 10-Q · filed 2015-02-13 |
| 2014-09-30 | $12.70M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $14.10M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $14.63M 10-K · filed 2015-06-10 | |
| 2013-12-31 | -$74.84M 10-K · filed 2016-03-10 | |
| 2013-03-31 | $47.00K 10-K · filed 2015-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |